medigraphic.com
ISSN 1561-2988 (Print)

2022, Number 4

<< Back Next >>

Rev Cubana Farm 2022; 55 (4)

Factors related to non-testing of drugs in patients with pulmonary tuberculosis

Gómez KJ, Luna MLC, Rojas ZCN, Pacheco LR, Rivera-Lozada O

Language: Spanish
References: 34
Page: 1-17
PDF size: 689.11 Kb.


ABSTRACT

Introduction: Drug-resistant tuberculosis is a serious public health problem worldwide. Its presence is associated with more expensive treatment, with more adverse effects, and with higher rates of treatment failure and mortality, which becomes a barrier to the control and eradication of drug-resistant tuberculosis. As part of the disease control guidelines, all patients previously treated for tuberculosis should be tested for drug susceptibility, an aspect that is not always fulfilled.
Objective: To determine the frequency and factors related to non-performance of drug susceptibility testing in previously treated patients with pulmonary tuberculosis.
Methods: Operations research through a descriptive observational cross-sectional study of the registries of patients with pulmonary tuberculosis previously treated in Cali between 2017 and 2019. Data were obtained from the registries of the "Cali Tuberculosis Program.
Results: 369 records of patients with pulmonary tuberculosis previously treated were analyzed; it was found that the frequency of not performing the drug susceptibility test was 33.79 % in 2017; 44.88% in 2018 and 48.45% in 2019. The main risk conditions related to not performing susceptibility tests to drugs were drug dependence (36.67%), street habitability (30%) and prison confinement (21.11%). The variable patients without health insurance was the only significant one in the bivariate analysis (OR of 2.31 p = 0.0014).
Conclusions: To ensure that 100% of previously treated patients are tested for susceptibility to drugs, it is necessary to integrate those who participate in their timely access, guarantee the quality management of their processes and that the health personnel involved know the algorithms that the World Health Organization and the Ministry of Colombia have drawn up for the diagnosis and treatment of tuberculosis.


REFERENCES

  1. World Health Organization. Global tuberculosis report 2021. Geneva: WHO; 2021[acceso10/03/2022]. Disponible en:https://www. who. int/publications/i/item/9789240037021

  2. World Health Organization. Tuberculosis country profiles. Geneva: WHO; 2021 [acceso08/02/2022]. Disponible en: http://www. who. int/tb/country/data/profiles/en/

  3. Dean A, Cox H, Zignol M. Epidemiology of Drug-Resistant Tuberculosis. Adv Exp MedBiol. 2017;1019:209-220. DOI: 10. 1007/978-3-319-64371-7_11.

  4. Rivera O, Benites S, Mendigure J, Bonilla CA. Abandono del tratamiento en tuberculosismultirresistente: factores asociados en una región con alta carga de la enfermedad en Perú. Biomédica. 2019 [acceso11/12/2020];39(Supl. 2):44-7. Disponible en:https://revistabiomedica. org/index. php/biomedica/article/view/4564

  5. World Health Organization. Global tuberculosis report 2019. Geneva: WHO; 2019 [acceso05/02/2022]. Disponible en: https://www. who. int/publications/i/item/9789241565714

  6. Bahraminia F, Azimi T, Zangiabadian M, Nasiri M, Goudarzi M, Dadashi M, et al. Rifampicin-resistant tuberculosis in Iran: A systematic review and meta-analysis. Iran J BasicMed Sci. 2021;24(6):720-5. DOI: 10. 22038/ijbms. 2021. 47360. 10901.

  7. Cox V, McKenna L, Acquah R, Reuter A, Wasserman S, Vambe D, et al. Clinicalperspectives on treatment of rifampicin-resistant/multidrug-resistant TB. Int J Tuberc LungDis. 2020 [acceso 05/02/2022];24:1134-44. Disponible en:https://www. ingentaconnect. com/content/iuatld/ijtld/2020/00000024/00000011/art00002#

  8. Bonilla C, Rivera IC, Rivera O. Determinants of multi-drug resistant tuberculosistreatment failure in a prevalent region in Peru. Pak J Med Health Sci. 2020 [acceso15/03/2022];14(3):1013-18. Disponible en: https://pjmhsonline. com/2020/july-sep/1013. pdf

  9. Phu PT, Vinh DN, Son VT, Hanh NT, Lan NH, Van Vinh T, et al. Risk factors for poortreatment outcomes of 2266 multidrug-resistant tuberculosis cases in Ho Chi Minh City: aretrospective study. BMC Infect Dis. 2020;20:1-10. DOI: 10. 1186/s12879-020-4887-1.

  10. Ministerio de Salud y Protección Social. Programa Nacional de Prevención y Control dela Tuberculosis. Base nominal de seguimiento de casos año 2020. Presentacióncomportamiento de la tuberculosis en Colombia. MINSA. Bogotá; 2021 [acceso:23/03/2022] Disponible en:https://www. minsalud. gov. co/salud/publica/PET/Paginas/Tuberculosis. aspx

  11. Ministerio de Salud y Protección Social [internet]. Programa Nacional de Prevención yControl de la Tuberculosis. Base de datos del año 2019. MINSA. Bogotá; 2021 [acceso:28/03/2022]. Disponible en: http://www. tuberculosis. minsa. gob. pe/

  12. Bonilla C, Rivera IC, Rivera O. Barriers to accessing health services and their associationwith treatment adherence in tuberculosis patients at a hospital in Peru. Pak J Med Health Sci. 2020;14(3):1296-1304. Disponible en: https://pjmhsonline. com/2020/july-sep/1296. pdf

  13. Ministerio de Salud y Protección Social. Plan Estratégico hacia el fin de la Tuberculosisen Colombia 2016-2025. MINSA. Bogotá. 2016 [acceso 15/05/2021]. Disponible en:https://www. minsalud. gov. co/sites/rid/Lists/BibliotecaDigital/RIDE/INEC/INTOR/Plan-estrategico-fin-tuberculosis-colombia-2016-2025. pdf

  14. Ministerio de Salud y Protección Social. Resolución 227 de 2020, por la cual se adoptanlos lineamientos técnicos y operativos del Programa Nacional de Prevención y Control de laTuberculosis. Minsa. Bogotá; 2020 [acceso 28/11/2021]. Disponible enhttps://www. minsalud. gov. co/Normatividad_Nuevo/Forms/DispForm. aspx?ID=5901

  15. Agredo F, Osorio L. Coverage and fidelity of the Xpert MTB/RIF™ implementation in ahigh-burden area for pulmonary tuberculosis in Colombia. Cobertura y fidelidad de la pruebaXpert MTB/RIF™ en un área de alta carga de tuberculosis pulmonar en Colombia. Biomédica. 2020;40(4):626-640. DOI:10. 7705/biomedica. 5272.

  16. Martínez A, Chávez M. Caracterización clínica y terapéutica de pacientes con TBpulmonar en Cali. Av. Enferm. 2017;(35):324-33. DOI: 10. 15446/av. enferm. v35n3,62733.

  17. Córdoba C, Buriticá PA, Pacheco R, Mancilla A, Valderrama A, Bergonzoli G. Factoresde riesgo asociados con recaídas de tuberculosis pulmonar en Cali, Colombia. Biomédica. 2020;40 (Supl. 1):102-12. DOI:10. 7705/biomedica. 5061.

  18. Nieto LM, Ferro BE, Diaz G, Anthony RM, de Beer J, van Soolingen D. Genetic profilingof Mycobacterium tuberculosis revealed "modern" Beijing strains linked to MDR-TB fromSouthwestern Colombia. PLoS One. 2020;15(4). DOI: 10. 1371/journal. pone. 0224908.

  19. Ministerio de Salud y Protección Social. Programa Nacional de Prevención y Control dela Tuberculosis – PNPCT. Situación de la TB en Colombia: avances en el Plan EstratégicoNacional. MINSA. Bogotá. 2020. Disponible en:https://www. minsalud. gov. co/salud/publica/PET/Paginas/Tuberculosis. aspx

  20. Ruíz F, Arzuza L, Guerra M, Yesid R. Perfil de resistencia del Mycobacteriumtuberculosis a fármacos antituberculosos de primera línea y sus combinaciones. Rev CubanaMed Trop. 2020 [acceso 15/08/2021];72(2):1-16. Disponible en:http://www. revmedtropical. sld. cu/index. php/medtropical/article/view/525/345

  21. Dueñes M, Cardona D. Factores relacionados con el cumplimiento del tratamiento enpacientes con tuberculosis, Pereira, Colombia, 2012-2013. Biomédica. 2016 [acceso:08/02/2022];36(3):423-31. Disponible en:https://revistabiomedica. org/index. php/biomedica/article/view/2904

  22. Rodríguez E, Mondragón CH. Adherencia a la terapia farmacológica y sus factoresdeterminantes en pacientes con tuberculosis de un centro de salud de Santiago de Cali. RevColomb Cienc Quím Farm. 2014 [acceso: 08/06/2022];43:104-19. Disponible en:http://www. scielo. org. co/pdf/rccqf/v43n1/v43n1a07. pdf

  23. Gómez VJ, Gómez AJ, Robledo J, Hernández JM. Resistencia a Medicamentos enMycobacterium tuberculosis: contribución de mecanismos constitutivos y adquiridos. RevSalud Pública. 2018;20(4):491-7. DOI: 10. 15446/rsap. V20n4. 50575.

  24. Realpe T, Correa N, Rozo JC, Ferro BE, Gomez V, Zapata E, et al. Population Structureamong Mycobacterium tuberculosis Isolates from Pulmonary Tuberculosis Patients inColombia. PLoS One. 2014 [acceso 15/10/2020];9(4):1-12. Disponible en:https://journals. plos. org/plosone/article?id=10. 1371/journal. pone. 0093848

  25. Tejada Vergara B, Villadiego Chamorro M, Amador Ahumada C. Efectividad delPrograma de Control de Tuberculosis en las entidades estatales. Departamento de Córdoba-Colombia 2015. RAS. 2018 [acceso 08/02/2022];2(2):29-8. Disponible en:https://revistas. unicordoba. edu. co/index. php/avancesalud/article/view/1455

  26. Robledo J. Control de la tuberculosis multirresistente a fármacos: un objetivo posible. Biomédica. 2019 septiembre [acceso 08/02/2022];39(3):431-3. Disponible en:http://www. scielo. org. co/scielo. php?script=sci_arttext&pid=S0120-41572019000300431&lng

  27. Sousa G, Araujo T, Menino T, Teixeira J, Moreira T, Duarte M. Prevalence andassociated factors of tuberculosis treatment abandonment. Rev Esc Enferm USP. 2021;55:e03767. DOI: 10. 1590/S1980-220X2020039203767.

  28. Nunes L, Moura L, Oliveira J, Loret C, Cardozo R. Relationship between multimorbidityand the outcome of the treatment for pulmonary tuberculosis. Rev Gaucha Enferm. 2020;4:e20190373. DOI: 10. 1590/1983-1447. 2020. 20190373.

  29. Arroyo LH, Yamamura M, Ramos ACV, Campoy LT, Crispim JA, Berra TZ et al. Determinants of multidrug-resistant tuberculosis in São Paulo-Brazil: a multilevel Bayesiananalysis of factors associated with individual, community and access to health services. TropMed Int Health. 2020;25(7):839-49. DOI: 10. 1111/tmi. 13409.

  30. Mhimbira FA, Cuevas LE, Dacombe R, Mkopi A, Sinclair D. Interventions to increasetuberculosis case detection at primary healthcare or community-level services. CochraneDatabase Syst Rev. 2017;11(11):CD011432. DOI: 10. 1002/14651858. CD011432. pub2.

  31. Alagna R, Combary A, Tagliani E, Sawadogo LT, Saouadogo T, Diandé S, et al. Isdeployement of diagnostic test alone enough? Comprehensive package of interventions to strengthen TB laboratory network: three years of experience in Burkina Faso. BMC Infect Dis. 2021;21(1):346. DOI: 10. 1186/s12879-021-06012.

  32. Subbaraman R, Nathavitharana RR, Mayer KH, Satyanarayana S, Chadha VK,Arinaminpathy N et al. Constructing care cascades for active tuberculosis: a strategy forprogram monitoring and identifying gaps in quality of care. PLoS Med. 2019;16(2):e1002754. DOI: 10. 1371/journal. pmed. 1002754.

  33. Bonilla-Asalde C, Rivera-Lozada I, Rivera-Lozada O. Factores asociados al estigma enpersonas afectadas por tuberculosis en una región peruana de alto riesgo. Revista Cubana deInvestigaciones Biomédicas. 2021 [acceso 08/02/2022];40(2). Disponible en:http://www. revibiomedica. sld. cu/index. php/ibi/article/view/721

  34. Bezerra WDSP, Lemos EF, do Prado TN et al. Risk Stratification and Factors Associatedwith Abandonment of Tuberculosis Treatment in a Secondary Referral Unit. Patient PreferAdherence. 2020;14:2389-97. DOI:10. 2147/PPA. S266475.




2020     |     www.medigraphic.com